A Look At AbCellera Biologics (ABCL) Valuation After Annual Earnings Reveal Higher Revenue And A Narrower Net Loss

AbCellera Biologics (ABCL) is back in focus after releasing full year 2025 results, reporting revenue of US$75.13 million compared with US$28.83 million a year earlier and a net loss of US$146.41 million compared with US$162.86 million.

See our latest analysis for AbCellera Biologics.

AbCellera Biologics’ latest earnings drop comes after a mixed period for investors, with a 1-month share price return of 11.39% but a 3-year total shareholder return decline of 52.56% and a 5-year total shareholder return decline of 90.63%, while the 1-year total shareholder return of 60% hints that sentiment has improved recently.

If you are watching how biotech moves around earnings updates and want to broaden your search, take a look at 32 healthcare AI stocks as a starting list of ideas.

With revenue at US$75.13 million, a net loss of US$146.41 million and the share price far below its 5 year level, investors may now be asking whether AbCellera is undervalued or whether the market is already pricing in future growth.

Most Popular Narrative: 64.2% Undervalued

At a last close of $3.52 against a widely followed fair value estimate of $9.83, the current price sits well below that narrative anchor, which is built around AbCellera’s move into clinical programs and manufacturing.

The completion of AbCellera’s integrated clinical manufacturing capabilities by the end of 2025 is likely to enhance operational efficiency and reduce COGS, potentially improving net margins as the company begins utilization of these capabilities. Financial backing with over $630 million in liquidity and additional funding commitments provides AbCellera with the necessary resources to support long term pipeline development, enhancing potential future earnings through successful commercialization of their clinical candidates.

Read the complete narrative.

Curious what justifies a fair value nearly three times the share price? The narrative leans heavily on rapid revenue expansion, margin uplift and a rich future earnings multiple. Want to see how those assumptions fit together and what they imply for long term returns?

Result: Fair Value of $9.83 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, this hinges on clinical success and partner momentum; setbacks for ABCL635 or weaker milestone and royalty flows could quickly challenge the optimistic story.

Find out about the key risks to this AbCellera Biologics narrative.

Another View: High P/S Puts The Brakes On The Undervalued Story

That $9.83 fair value hinges on future cash flows and clinical success, but the current P/S of 14.2x tells a very different story. It sits well above the US Life Sciences average of 2.8x, the peer average of 3.7x, and a fair ratio of just 0.3x, which points to heavy valuation risk if growth or margins disappoint. This raises a key question: is this a genuine disconnect to lean into, or a warning sign to treat the optimistic narrative with caution?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

The mix of optimism and caution around AbCellera is clear, so review the details while they are fresh and form your own view using 1 key reward and 3 important warning signs.

Looking for more investment ideas?

If you want to widen your watchlist beyond AbCellera, now is the moment to act; fresh ideas often show up before the story hits the headlines.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com